SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is trending downward following a significant post-earnings sell-off driven by weak future sales guidance and concerns over the company's turnaround progress in key international markets. The investor community remains sharply divided, with some actively buying the dip as a long-term value play, while others criticize the brand's loss of cultural relevance and competitive positioning against emerging sportswear rivals.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is seeing heightened attention following a fiscal third-quarter earnings beat, though investor sentiment remains divided between optimism over potential cannabis policy shifts and concerns regarding the company's persistent cash burn and the performance of its beverage segment. The community is actively debating the company's long-term turnaround strategy, the impact of anticipated U.S. federal regulatory changes, and the leadership of CEO Irwin Simon.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is generating significant buzz as investors track positive Phase 3 clinical data for its lead skin disease treatment, sonelokimab, while speculating on the potential for a high-premium buyout. The community remains deeply divided, with some retail investors holding for generational wealth based on clinical performance while others warn of price manipulation, short-selling pressure, and the impact of institutional divestments.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending as investors debate the impact of broader geopolitical tensions and energy price volatility on the company's turnaround efforts and fab expansion. While the community is divided between skepticism over short-term price swings and bullish sentiment regarding the company's long-term manufacturing moat, active discussions are focused on whether recent technical bounces signal a sustained recovery or are merely temporary relief in a highly manipulated environment.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is experiencing heightened investor interest following the announcement of a massive multi-year AI cloud infrastructure agreement, which has sparked intense debate over the stock's potential for a significant short squeeze. Community members are actively discussing the company's low float and the strategic impact of this contract, leading to speculation about aggressive price moves while some remain cautious of potential spoofing and market volatility.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is experiencing significant downward pressure as investors weigh weak earnings and revenue misses against the company's aggressive but costly international expansion. Market sentiment is sharply divided, with bearish traders highlighting high debt levels and persistent housing sector headwinds, while bullish investors are betting on a potential short squeeze fueled by high short interest and speculative hopes for future tariff relief.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors monitor ongoing project developments, including the upcoming pilot plant operations and the status of the Definitive Feasibility Study. Market participants are actively debating the stock's valuation relative to its rare earth assets while navigating volatility driven by broader sector trends and geopolitical developments.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors gear up for the upcoming 10-K filing and earnings report, with community members closely tracking the company's aggressive debt reduction efforts and the performance of key holdings like Applied Digital and BW. Bullish participants are actively discussing a potential valuation re-rating and the possibility of a short squeeze, while keeping a watchful eye on management's next steps to address previous legal overhangs and restore institutional confidence.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors focus on the commercial launch of YARTEMLEA, with the community closely tracking initial patient uptake, formulary approvals at major transplant centers, and the company's timeline for reaching positive cash flow. While the stock has faced downward pressure due to technical factors and broader market volatility, discussions are heavily centered on upcoming Q1 sales updates, the potential for milestone payments from the Novo Nordisk partnership, and imminent EU regulatory milestones.

FUST (Fusion token) is the companion token of FUSD - with tokenomics which mirror those of a typical cryptocurrency. FUST can be placed in the FUST Fusion Miner and used to mine free FUSD. FUST has tokenomics which mirror those of a typical cryptocurrency, and allows those Degens who buy into the FUSD philosophy - but who also enjoy the thrill of chasing fast green candles - to make their play within the structure of the FUSD ecosystem and benefit from the best of both worlds; the possibility of a fast ride upwards whilst earning a passive income paid in our appreciating stable token courtesy of their FUST bag.

FUST Token

FUST is gaining significant traction as investors highlight its ecosystem's focus on sustainable utility and passive income generation through its unique appreciating stablecoin, FUSD. The community is actively discussing upcoming project milestones, including an NFT platform launch and ongoing distribution events, as they position themselves for potential long-term growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year High - Here's What Happened

Royalty Pharma (NASDAQ:RPRX) Hits New 12-Month High - Here's Why...

SG Americas Securities LLC Buys 234,629 Shares of Royalty Pharma PLC $RPRX

SG Americas Securities LLC lifted its stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 438.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 288,202 shares of the biopharmaceutical company's stock afte...

Royalty Pharma PLC $RPRX Shares Sold by Cooper Investors PTY Ltd.

Cooper Investors PTY Ltd. lowered its stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 5.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the...

Wedge Capital Management L L P NC Lowers Stock Position in Royalty Pharma PLC $RPRX

Wedge Capital Management L L P NC decreased its holdings in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 12.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,039,968 shares of the biopharmaceutical...

Wealth Enhancement Advisory Services LLC Buys 165,451 Shares of Royalty Pharma PLC $RPRX

Wealth Enhancement Advisory Services LLC grew its position in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 701.2% during the 4th quarter, according to its most recent 13F filing with the SEC...

Why Is Mirum Pharmaceuticals (MIRM) Down 3.6% Since Last Earnings Report?

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Royalty Pharma PLC (NASDAQ:RPRX) Given Average Rating of "Buy" by Analysts

Shares of Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) have been given a consensus recommendation of "Buy" by the six research firms that are covering the stock, Marketbeat Ratings reports. Six...

Why Is Apellis Pharmaceuticals (APLS) Down 17.3% Since Last Earnings Report?

Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Royalty Pharma (NASDAQ:RPRX) CFO Sells $1,584,034.23 in Stock

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) CFO Terrance Coyne sold 34,791 shares of the firm's stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average...

Insider Selling: Royalty Pharma (NASDAQ:RPRX) CFO Sells 34,791 Shares of Stock

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) CFO Terrance Coyne sold 34,791 shares of Royalty Pharma stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $45.53, for a total transaction of $1,584,034.23. Following the sale, the chief financial officer...

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Royalty Pharma plc - Ordinary Shares - Class A

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

RPRX
Royalty Pharma plc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RPRX News

RPRXRoyalty Pharma plc - Ordinary Shares - Class A